The Company has acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis pursuant to the BTA Agreement as on 30.06.2025. Accordingly the LLP has ceased ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Aspira Pathlab & Diagnostics, at its meeting on November 12, 2025, approved the unaudited standalone financial results for Q2/H1 FY26 ended September 30, 2025. Revenue from operations rose to Rs. 809.28 lakhs in Q2 FY26 from Rs. 617.76 lakhs in Q2 FY25, while profit after tax jumped sharply to Rs. 183.54 lakhs from Rs. 99.03 lakhs year-on-year. The company also disclosed that it has acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for Rs. 13.00 lakhs, effective from June 30, 2025, with the LLP now winding up under the LLP Act, 2008. Consequently, the company no longer has any subsidiary, associate, or joint venture, and consolidated results will not be presented from this quarter. Additionally, Mrs. Kiran Raghavendra Awasthi (Chartered Accountant with 28+ years' experience) was appointed as Additional Independent Director for a five-year term.
Positive for shareholders — strong YoY revenue and profit growth in Q2 FY26, and the Gujarat LLP acquisition consolidates the company's diagnostic operations in the region. The deal size is small (Rs. 13 lakhs) so financial impact is limited, but the move streamlines the group structure with no further subsidiary/JV obligations.